

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Temozolomide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.01.2025
9.2	14.04.2025	25445-00032	Date of first issue: 24.10.2014

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Temozolomide Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-
stance/Mixture : Pharmaceutical

Recommended restrictions
on use : Not applicable

1.3 Details of the supplier of the safety data sheet

Company : MSD
Innishannon
County Cork - Ireland

Telephone : 353 214329300

E-mail address of person
responsible for the SDS : EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

+1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Acute toxicity, Category 4	H302: Harmful if swallowed.
Eye irritation, Category 2	H319: Causes serious eye irritation.
Germ cell mutagenicity, Category 2	H341: Suspected of causing genetic defects.
Carcinogenicity, Category 2	H351: Suspected of causing cancer.
Reproductive toxicity, Category 1B	H360FD: May damage fertility. May damage the unborn child.
Specific target organ toxicity - repeated exposure, Category 1	H372: Causes damage to organs through prolonged or repeated exposure.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Temozolomide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.01.2025
9.2	14.04.2025	25445-00032	Date of first issue: 24.10.2014

Hazard pictograms

:



Signal word

:

Danger

Hazard statements

:

H302	Harmful if swallowed.
H319	Causes serious eye irritation.
H341	Suspected of causing genetic defects.
H351	Suspected of causing cancer.
H360FD	May damage fertility. May damage the unborn child.
H372	Causes damage to organs through prolonged or repeated exposure.

Precautionary statements

:

Prevention:

P201	Obtain special instructions before use.
P260	Do not breathe dust.
P270	Do not eat, drink or smoke when using this product.
P280	Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P308 + P313	IF exposed or concerned: Get medical advice/ attention.
P337 + P313	If eye irritation persists: Get medical advice/ attention.

Hazardous components which must be listed on the label:

Temozolomide

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Temozolomide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.01.2025
9.2	14.04.2025	25445-00032	Date of first issue: 24.10.2014

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Temozolomide	85622-93-1	Acute Tox. 4; H302 Muta. 2; H341 Carc. 2; H351 Repr. 1B; H360FD STOT RE 1; H372 (Bone marrow, thymus gland, Lymph nodes, spleen)	$\geq 50 - < 70$
(+)-Tartaric acid	87-69-4 201-766-0	Eye Dam. 1; H318	$\geq 1 - < 3$

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

- | | |
|----------------------------|---|
| General advice | : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice. |
| Protection of first-aiders | : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8). |
| If inhaled | : If inhaled, remove to fresh air.
Get medical attention. |
| In case of skin contact | : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse. |
| In case of eye contact | : In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.
If easy to do, remove contact lens, if worn.
Get medical attention. |
| If swallowed | : If swallowed, DO NOT induce vomiting.
Get medical attention. |

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Temozolomide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.01.2025
9.2	14.04.2025	25445-00032	Date of first issue: 24.10.2014

Rinse mouth thoroughly with water.
Never give anything by mouth to an unconscious person.

4.2 Most important symptoms and effects, both acute and delayed

Risks : Contact with dust can cause mechanical irritation or drying of the skin.

Harmful if swallowed.
Causes serious eye irritation.
Suspected of causing genetic defects.
Suspected of causing cancer.
May damage fertility. May damage the unborn child.
Causes damage to organs through prolonged or repeated exposure.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical

Unsuitable extinguishing media : None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides
Nitrogen oxides (NO_x)
Metal oxides

5.3 Advice for firefighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Temozolomide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.01.2025
9.2	14.04.2025	25445-00032	Date of first issue: 24.10.2014

Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling : Do not get on skin or clothing.
Do not breathe dust.
Do not swallow.
Do not get in eyes.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Temozolomide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.01.2025
9.2	14.04.2025	25445-00032	Date of first issue: 24.10.2014

practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers : Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.

Advice on common storage : Do not store with the following product types:
Strong oxidizing agents
Self-reactive substances and mixtures
Organic peroxides
Explosives
Gases

7.3 Specific end use(s)

Specific use(s) : No data available
No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

dusts non-specific 4 mg/m³
Value type (Form of exposure): OELV - 8 hrs (TWA) (Respirable dust)
Basis: IE OEL

10 mg/m³
Value type (Form of exposure): OELV - 8 hrs (TWA) (inhalable dust)
Basis: IE OEL

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Temozolomide Formulation

Version 9.2 Revision Date: 14.04.2025 SDS Number: 25445-00032 Date of last issue: 23.01.2025
Date of first issue: 24.10.2014

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Temozolomide	85622-93-1	TWA	0.1 ug/m3 (OEB 5)	Internal
		Wipe limit	1 µg/100 cm2	Internal
Stearic acid	57-11-4	OELV - 8 hrs (TWA)	10 mg/m3	IE OEL

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006

Substance name	End Use	Exposure routes	Potential health effects	Value
(+)-Tartaric acid	Workers	Inhalation	Long-term systemic effects	5.2 mg/m3
	Workers	Skin contact	Long-term systemic effects	2.9 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic effects	1.3 mg/m3
	Consumers	Skin contact	Long-term systemic effects	1.5 mg/kg bw/day
	Consumers	Ingestion	Long-term systemic effects	8.1 mg/kg bw/day
Stearic acid	Workers	Inhalation	Long-term systemic effects	17.63 mg/m3
	Workers	Skin contact	Long-term systemic effects	10 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic effects	4.348 mg/m3
	Consumers	Skin contact	Long-term systemic effects	5 mg/kg bw/day
	Consumers	Ingestion	Long-term systemic effects	2.5 mg/kg bw/day

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006

Substance name	Environmental Compartment	Value
Temozolomide	Fresh water	0.08 mg/l
	Marine water	0.08 mg/l
(+)-Tartaric acid	Fresh water	0.3125 mg/l
	Freshwater - intermittent	0.514 mg/l
	Marine water	0.3125 mg/l
	Sewage treatment plant	10 mg/l
	Fresh water sediment	1.141 mg/kg dry weight (d.w.)
	Marine sediment	1.141 mg/kg dry weight (d.w.)
	Soil	0.0449 mg/kg dry weight (d.w.)

8.2 Exposure controls

Engineering measures

The information below is intended for larger pilot/commercial-scale operations and manufacturing. For smaller scale, clinical, or pharmacy settings, site-specific internal risk assessment practices

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Temozolomide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.01.2025
9.2	14.04.2025	25445-00032	Date of first issue: 24.10.2014

should be conducted to determine appropriate exposure control measures. The health hazard risks of handling this material are dependent on multiple factors, including but not limited to physical form and quantity handled. If applicable, use process enclosures, local exhaust ventilation (e.g., Biosafety Cabinet, Ventilated Balance Enclosures), or other engineering controls to maintain airborne levels below recommended exposure limits. If exposure limits have not been established, maintain airborne levels as low as reasonably achievable.

Use closed processing systems or containment technologies to control at source (e.g., glove boxes/isolators) and to prevent leakage of compounds into the workplace.

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

No open handling permitted.

Totally enclosed processes and materials transport systems are required.

Operations require the use of appropriate containment technology designed to prevent leakage of compounds into the workplace.

Personal protective equipment

Eye/face protection : Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Skin and body protection : Work uniform or laboratory coat.
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
Use appropriate degowning techniques to remove potentially contaminated clothing.

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Equipment should conform to I.S. EN 143

Filter type : Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state : powder

Colour : off-white

Odour : No data available

Odour Threshold : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling : No data available

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Temozolomide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.01.2025
9.2	14.04.2025	25445-00032	Date of first issue: 24.10.2014

range

Flammability (solid, gas) : May form explosive dust-air mixture during processing, handling or other means.

Flammability (liquids) : No data available

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Flash point : No data available

Auto-ignition temperature : No data available

Decomposition temperature : No data available

pH : No data available

Viscosity

Viscosity, kinematic : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-octanol/water : No data available

Vapour pressure : No data available

Relative density : No data available

Density : 1 g/cm³

Relative vapour density : No data available

Particle characteristics

Particle size : No data available

9.2 Other information

Explosives : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Evaporation rate : No data available

Molecular weight : No data available

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Temozolomide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.01.2025
9.2	14.04.2025	25445-00032	Date of first issue: 24.10.2014

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.
Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : Heat, flames and sparks.
Avoid dust formation.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of exposure : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Harmful if swallowed.

Product:

Acute oral toxicity : Acute toxicity estimate: 562.5 mg/kg
Method: Calculation method

Components:

Temozolomide:

Acute oral toxicity : LD50 (Dog): 19 mg/kg
LD50 (Rat): 315 mg/kg
LD50 (Mouse): 205 mg/kg

(+)-Tartaric acid:

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Temozolomide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.01.2025
9.2	14.04.2025	25445-00032	Date of first issue: 24.10.2014

Acute oral toxicity	:	LD50 (Rat): > 2,000 mg/kg Method: OECD Test Guideline 423
Acute dermal toxicity	:	LD50 (Rat): > 2,000 mg/kg Method: OECD Test Guideline 402 Assessment: The substance or mixture has no acute dermal toxicity

Skin corrosion/irritation

Not classified based on available information.

Components:

(+)-Tartaric acid:

Species	:	Rabbit
Method	:	OECD Test Guideline 404
Result	:	No skin irritation

Serious eye damage/eye irritation

Causes serious eye irritation.

Components:

(+)-Tartaric acid:

Species	:	Bovine cornea
Method	:	OECD Test Guideline 437
Result	:	Irreversible effects on the eye

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

Temozolomide:

Test Type	:	Maximisation Test
Exposure routes	:	Dermal
Species	:	Guinea pig
Result	:	negative

(+)-Tartaric acid:

Test Type	:	Local lymph node assay (LLNA)
Exposure routes	:	Skin contact
Species	:	Mouse
Method	:	OECD Test Guideline 429
Result	:	negative

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Temozolomide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.01.2025
9.2	14.04.2025	25445-00032	Date of first issue: 24.10.2014

Germ cell mutagenicity

Suspected of causing genetic defects.

Components:

Temozolomide:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: positive

Test Type: Chromosome aberration test in vitro
Test system: Human lymphocytes
Result: positive

Germ cell mutagenicity- Assessment : Positive results from in vitro mammalian mutagenicity assays, chemical structure activity relationship to known germ cell mutagens

(+)-Tartaric acid:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro
Result: negative
Remarks: Based on data from similar materials

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
Result: positive

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
Species: Rat
Application Route: Ingestion
Result: negative

Carcinogenicity

Suspected of causing cancer.

Components:

Temozolomide:

Species : Rat
Application Route : Oral
Exposure time : 6 Months
: 4 mg/kg body weight
Result : positive
Target Organs : Mammary gland

Carcinogenicity - Assessment : Limited evidence of carcinogenicity in animal studies

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Temozolomide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.01.2025
9.2	14.04.2025	25445-00032	Date of first issue: 24.10.2014

Reproductive toxicity

May damage fertility. May damage the unborn child.

Components:

Temozolomide:

Effects on fertility	:	Test Type: Fertility/early embryonic development Species: Rat, male Application Route: Oral Fertility: LOAEL: 8.5 mg/kg body weight Result: positive
Effects on foetal development	:	Test Type: Embryo-foetal development Species: Rat Application Route: Oral Embryo-foetal toxicity: LOAEL: 13 mg/kg body weight Result: positive, Malformations were observed.
Reproductive toxicity - Assessment	:	Clear evidence of adverse effects on sexual function and fertility, based on animal experiments., Clear evidence of adverse effects on development, based on animal experiments.

(+)-Tartaric acid:

Effects on foetal development	:	Test Type: Embryo-foetal development Species: Rat Application Route: Ingestion Result: negative
-------------------------------	---	--

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Causes damage to organs through prolonged or repeated exposure.

Components:

Temozolomide:

Exposure routes	:	Ingestion
Target Organs	:	Bone marrow, thymus gland, Lymph nodes, spleen
Assessment	:	Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Temozolomide:

Species	:	Rat, female
NOAEL	:	4 mg/kg
LOAEL	:	21 mg/kg
Application Route	:	Oral
Exposure time	:	6 Months

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Temozolomide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.01.2025
9.2	14.04.2025	25445-00032	Date of first issue: 24.10.2014

Target Organs : thymus gland, Bone marrow, Reproductive organs, Lymph nodes

Species : Rat, male

NOAEL : 8.5 mg/kg

LOAEL : 34 mg/kg

Application Route : Oral

Exposure time : 6 Months

Target Organs : thymus gland, Bone marrow, male reproductive organs, Gastrointestinal tract, Lymph nodes

Species : Dog

NOAEL : 2.5 mg/kg

LOAEL : 6.3 mg/kg

Application Route : Oral

Exposure time : 6 Months

Target Organs : Bone marrow, spleen, male reproductive organs, Gastrointestinal tract, thymus gland

(+)-Tartaric acid:

Species : Rat

NOAEL : > 100 mg/kg

Application Route : Ingestion

Exposure time : 2 yr

Aspiration toxicity

Not classified based on available information.

11.2 Information on other hazards

Endocrine disrupting properties

Not classified based on available information.

Product:

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Experience with human exposure

Components:

Temozolomide:

Ingestion : Symptoms: Blood disorders, Nausea, Vomiting, Diarrhoea, anorexia, Fatigue, hair loss

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Temozolomide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.01.2025
9.2	14.04.2025	25445-00032	Date of first issue: 24.10.2014

SECTION 12: Ecological information

12.1 Toxicity

Components:

Temozolomide:

Toxicity to fish	: LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l Exposure time: 96 h Method: OECD Test Guideline 203
Toxicity to daphnia and other aquatic invertebrates	: EC50 (Daphnia magna (Water flea)): > 100 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
Toxicity to algae/aquatic plants	: EC50 (Pseudokirchneriella subcapitata (green algae)): > 90 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 NOEC (Pseudokirchneriella subcapitata (green algae)): 40 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
Toxicity to microorganisms	: EC50 : > 100 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209

(+)-Tartaric acid:

Toxicity to fish	: LC50 (Danio rerio (zebra fish)): > 100 mg/l Exposure time: 96 h Method: OECD Test Guideline 203
Toxicity to daphnia and other aquatic invertebrates	: EC50 (Daphnia magna (Water flea)): 93.313 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
Toxicity to algae/aquatic plants	: EC50 (Pseudokirchneriella subcapitata (green algae)): 51.404 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 NOEC (Pseudokirchneriella subcapitata (green algae)): 3.125 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
Toxicity to microorganisms	: EC50 : > 1,000 mg/l Exposure time: 3 h Method: OECD Test Guideline 209

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Temozolomide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.01.2025
9.2	14.04.2025	25445-00032	Date of first issue: 24.10.2014

12.2 Persistence and degradability

Components:

Temozolomide:

Biodegradability	:	Result: rapidly degradable Biodegradation: 83 % Exposure time: 35 d
Stability in water	:	Degradation half life (DT50): < 1 d

(+)-Tartaric acid:

Biodegradability	:	Result: Readily biodegradable. Biodegradation: 85 % Exposure time: 28 d Method: OECD Test Guideline 306
------------------	---	--

12.3 Bioaccumulative potential

Components:

Temozolomide:

Partition coefficient: n-octanol/water	:	log Pow: 1.35
--	---	---------------

(+)-Tartaric acid:

Partition coefficient: n-octanol/water	:	log Pow: -1.91
--	---	----------------

12.4 Mobility in soil

No data available

12.5 Results of PBT and vPvB assessment

Product:

Assessment	:	This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
------------	---	--

12.6 Endocrine disrupting properties

Product:

Assessment	:	The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
------------	---	---

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Temozolomide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.01.2025
9.2	14.04.2025	25445-00032	Date of first issue: 24.10.2014

12.7 Other adverse effects

No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product	: Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.
Contaminated packaging	: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number

ADN	: Not regulated as a dangerous good
ADR	: Not regulated as a dangerous good
RID	: Not regulated as a dangerous good
IMDG	: Not regulated as a dangerous good
IATA	: Not regulated as a dangerous good

14.2 UN proper shipping name

ADN	: Not regulated as a dangerous good
ADR	: Not regulated as a dangerous good
RID	: Not regulated as a dangerous good
IMDG	: Not regulated as a dangerous good
IATA	: Not regulated as a dangerous good

14.3 Transport hazard class(es)

ADN	: Not regulated as a dangerous good
ADR	: Not regulated as a dangerous good
RID	: Not regulated as a dangerous good
IMDG	: Not regulated as a dangerous good
IATA	: Not regulated as a dangerous good

14.4 Packing group

ADN	: Not regulated as a dangerous good
-----	-------------------------------------

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Temozolomide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.01.2025
9.2	14.04.2025	25445-00032	Date of first issue: 24.10.2014

ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
IATA (Cargo)	:	Not regulated as a dangerous good
IATA (Passenger)	:	Not regulated as a dangerous good

14.5 Environmental hazards

Not regulated as a dangerous good

14.6 Special precautions for user

Not applicable

14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII) : Not applicable

REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59). : Not applicable

Regulation (EU) No 2024/590 on substances that deplete the ozone layer : Not applicable

Regulation (EU) 2019/1021 on persistent organic pollutants (recast) : Not applicable

Regulation (EU) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals : Not applicable

REACH - List of substances subject to authorisation (Annex XIV) : Not applicable

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.
Not applicable

Other regulations:

Take note of Directive 92/85/EEC regarding maternity protection or stricter national regulations, where applicable.

Take note of Directive 94/33/EC on the protection of young people at work or stricter national regulations, where applicable.

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Temozolomide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.01.2025
9.2	14.04.2025	25445-00032	Date of first issue: 24.10.2014

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Statements

H302	: Harmful if swallowed.
H318	: Causes serious eye damage.
H341	: Suspected of causing genetic defects.
H351	: Suspected of causing cancer.
H360FD	: May damage fertility. May damage the unborn child.
H372	: Causes damage to organs through prolonged or repeated exposure if swallowed.

Full text of other abbreviations

Acute Tox.	: Acute toxicity
Carc.	: Carcinogenicity
Eye Dam.	: Serious eye damage
Muta.	: Germ cell mutagenicity
Repr.	: Reproductive toxicity
STOT RE	: Specific target organ toxicity - repeated exposure
IE OEL	: Ireland. List of Chemical Agents and Carcinogens with Occupational Exposure Limit Values - Code of Practice, Schedule 1 and 2
IE OEL / OELV - 8 hrs (TWA)	: Occupational exposure limit value (8-hour reference period)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Ef-

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Temozolomide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.01.2025
9.2	14.04.2025	25445-00032	Date of first issue: 24.10.2014

fect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Classification of the mixture:

Acute Tox. 4	H302
Eye Irrit. 2	H319
Muta. 2	H341
Carc. 2	H351
Repr. 1B	H360FD
STOT RE 1	H372

Classification procedure:

Calculation method
Calculation method
Calculation method
Calculation method
Calculation method
Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IE / EN